期刊文献+

10-羟基喜树碱半固体脂质纳米粒的研制与稳定性考察 被引量:6

Preparation of 10-hydroxycamptothecin Semisolid Lipid Nanoparticles and Investigation of Its Stability
在线阅读 下载PDF
导出
摘要 目的:制备10-羟基喜树碱的半固体脂质纳米粒(HCPT-SSLN)并考察其稳定性。方法:采用高温乳化蒸发-低温固体法制备了HCPT-SSLN;用透射电镜考察了纳米粒的形态;用激光粒度仪测定了粒径和ξ电位;考察了其混悬液和冻干粉的物理稳定性。结果:HCPT-SSLN纳米粒平均粒径为130.5 nm,载药量为2.51%,包封率为79.19%,ξ电位为-33.1mV;室温(25℃)和4℃下放置6个月,纳米粒外观、粒径及包封率无明显变化,冻干粉比混悬液的物理稳定性更高。结论:本实验制备的HCPT-SSLN包封率和载药量较高,粒径分布均匀,稳定性良好。初步表明HCPT适合进行SSLN包裹。 Objective: To prepare 10-hydroxycamptothecin-semisolid lipid nanoparticles (HCPT-SSLN) and investigate its stability. Methods: HCPT-SSLN was prepared by the method of “emulsion evaporation at a high temperature and solidification at a low temperature” ; The morphology was examined by transmission electron microscope; The particle size and ξ potential were determined by laser granularity equipment; The physical stability of both suspl and freeze drying powder of HCPT-SSLN were investigated. Results: The mean particle size of the prepared HCPT-SSLN was 130. 5 nm, drug loading was 2.51% , entrapment efficiency was 79. 19%, ξ potential was -33, 1mV; Placed at room temperature and 4℃ for 6 months, the appearance, particle size and entrapment efficiency of HCPT-SSLN were all stable. Moreover, the freeze drying powder was more stable than the suspl. Conclusion: The HCPT-SSLN has high entrapment efficiency and drug loading, uniform particle size, good stability, which initially indicates that HCPT is fit for being incorporated into SSLN.
出处 《中药材》 CAS CSCD 北大核心 2006年第1期63-66,共4页 Journal of Chinese Medicinal Materials
基金 广东省科技计划项目(2003A1070103)
关键词 10-羟基喜树碱 半固体脂质纳米粒 葡聚糖凝胶 10-hydroxycamptothecin Semisolid lipid nanoparticles (SSLN) Sephadex gel
  • 相关文献

参考文献6

  • 1Iyer L,Ratain M J.Clinical pharmacology of camptothecins.Cancer Chemother Parmacol,1998,41:31-43.
  • 2Urasaki Y,Laco G,Takebayashi Y,et al.Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase Ⅰ in the antiproliferative activity of the indolocarbazole,NB-506,and its topoisomerase Ⅰ binding site.Cancer Res,2001,61 (2):504-508.
  • 3Jung LL,Zamboni WC.Cellular,Pharmacokinetic,and pharmacodynamic aspects of response to camptothecins:can we improve it? Drug Ressistance Updates,2001,4(4):273-288.
  • 4张力,李苏,廖海,姜文奇,管忠震.羟基喜树碱Ⅰ期药代动力学及人体耐受性临床研究[J].癌症,2001,20(12):1391-1395. 被引量:81
  • 5Burke TG,Mishra Ak,Wani Mc,et al.Lipid bilayer partitioning and stability of Camptothecin drugs.Biochemistry,1993,32(20):5352-5364.
  • 6Müller RH,Radtke M,Wissing SA.Nanostructured lipid matrices for improved microencapsulation of drugs.Int J Pharm,2002,242(1-2):121-128.

二级参考文献7

共引文献80

同被引文献119

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部